NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
100 trialsNCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT04281576 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NovoCure Ltd.
Phase NA Completed
NCT02578368 2024-11-12
FLOT5
Krankenhaus Nordwest
Phase 3 Completed
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT03382600 2024-06-11
KEYNOTE-659
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02746796 2024-05-03
Study of ONO-4538 in Gastric Cancer
Ono Pharmaceutical Co. Ltd
Phase 2/3 Completed
NCT03006705 2024-05-03
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Ono Pharmaceutical Co. Ltd
Phase 3 Completed
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03607656 2023-12-18
CHANGE
Shanghai University of Traditional Chinese Medicine
Phase 2/3 Completed
NCT01515748 2023-12-13
PRODIGY
Sanofi
Phase 3 Completed
NCT02555358 2023-10-19
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage â…¢ Clinical Study
Hebei Medical University
Phase 2 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT01212822 2022-09-07
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT02725424 2022-08-17
MATCH
ChineseAMS
Phase 2 Completed
NCT02661971 2022-07-11
RAMSES/FLOT7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Completed
NCT01711242 2022-05-05
Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
Wenzhou Medical University
Phase 2 Completed
NCT01896531 2022-03-02
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Genentech, Inc.
Phase 2 Completed
NCT02322593 2021-12-20
SOLAR
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT02395640 2021-10-26
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Phase 3 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00952003 2020-11-30
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT01443065 2020-11-17
MEGA
UNICANCER
Phase 2 Completed
NCT02114359 2020-10-23
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
Seoul National University Hospital
Phase 3 Completed
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02545504 2020-05-26
GAMMA-1
Gilead Sciences
Phase 3 Completed
NCT01913639 2020-05-15
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01643499 2020-05-08
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
Phase 1 Completed
NCT01516944 2020-02-13
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Hebei Medical University
Phase 2/3 Completed
NCT00525785 2020-02-10
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01747551 2020-02-10
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00446290 2020-01-18
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Asan Medical Center
Phase 1 Completed
NCT00398398 2020-01-07
Study of XELOX With Cetuximab in Advanced Gastric Cancer
Asan Medical Center
Phase 2 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02301481 2019-10-16
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma
ChineseAMS
Phase 2 Completed
NCT01748773 2019-10-09
TOXAG
Hoffmann-La Roche
Phase 2 Completed